

Global Multivalent Influenza Vaccines Market Growth 2022-2028

<https://marketpublishers.com/r/G93E974CA330EN.html>

Date: December 2022

Pages: 111

Price: US\$ 3,660.00 (Single User License)

ID: G93E974CA330EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global market for Multivalent Influenza Vaccines is estimated to increase from US\$ million in 2021 to reach US\$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Multivalent Influenza Vaccines market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Multivalent Influenza Vaccines market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Multivalent Influenza Vaccines market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Multivalent Influenza Vaccines market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Multivalent Influenza Vaccines players cover Sanofi, CSL, GSK, Viartis and AstraZeneca, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage

This latest report provides a deep insight into the global Multivalent Influenza Vaccines market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Multivalent Influenza Vaccines market, with both quantitative and qualitative data, to help readers understand how the Multivalent Influenza Vaccines market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:

The study segments the Multivalent Influenza Vaccines market and forecasts the market size by Type (Trivalent Inactivated Influenza Vaccine (IIV3), Trivalent Live Attenuated Vaccine (LAIV3) and Quadrivalent Inactivated Influenza Vaccine (IIV4)), by Application (6 Months to 3 Years and Above 3 Years.), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type

Trivalent Inactivated Influenza Vaccine (IIV3)

Trivalent Live Attenuated Vaccine (LAIV3)

Quadrivalent Inactivated Influenza Vaccine (IIV4)

Segmentation by application

6 Months to 3 Years

Above 3 Years

Segmentation by region

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

Major companies covered

Sanofi

CSL

GSK

Viartis

AstraZeneca

Hualan Bio

Changchun Institute of Biological

Sinovac

Bcht Biotechnology

Jiangsu GDK

KM Biologics

ADIMMUNE Corporation

Aleph Biomedical

Shanghai Institute of Biological Products

Zhongyianke Biotech

Wuhan Institute of Biological Products

Chapter Introduction

Chapter 1: Scope of Multivalent Influenza Vaccines, Research Methodology, etc.

Chapter 2: Executive Summary, global Multivalent Influenza Vaccines market size (sales and revenue) and CAGR, Multivalent Influenza Vaccines market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.

Chapter 3: Multivalent Influenza Vaccines sales, revenue, average price, global market share, and industry ranking by company, 2017-2022

Chapter 4: Global Multivalent Influenza Vaccines sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.

Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.

Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace

Chapter 10: Manufacturing cost structure analysis

Chapter 11: Sales channel, distributors, and customers

Chapter 12: Global Multivalent Influenza Vaccines market size forecast by region, by country, by type, and application.

Chapter 13: Comprehensive company profiles of the leading players, including Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac

and Bcht Biotechnology, etc.

Chapter 14: Research Findings and Conclusion

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Multivalent Influenza Vaccines Annual Sales 2017-2028
 - 2.1.2 World Current & Future Analysis for Multivalent Influenza Vaccines by Geographic Region, 2017, 2022 & 2028
 - 2.1.3 World Current & Future Analysis for Multivalent Influenza Vaccines by Country/Region, 2017, 2022 & 2028
- 2.2 Multivalent Influenza Vaccines Segment by Type
 - 2.2.1 Trivalent Inactivated Influenza Vaccine (IIV3)
 - 2.2.2 Trivalent Live Attenuated Vaccine (LAIV3)
 - 2.2.3 Quadrivalent Inactivated Influenza Vaccine (IIV4)
- 2.3 Multivalent Influenza Vaccines Sales by Type
 - 2.3.1 Global Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
 - 2.3.2 Global Multivalent Influenza Vaccines Revenue and Market Share by Type (2017-2022)
 - 2.3.3 Global Multivalent Influenza Vaccines Sale Price by Type (2017-2022)
- 2.4 Multivalent Influenza Vaccines Segment by Application
 - 2.4.1 6 Months to 3 Years
 - 2.4.2 Above 3 Years
- 2.5 Multivalent Influenza Vaccines Sales by Application
 - 2.5.1 Global Multivalent Influenza Vaccines Sale Market Share by Application (2017-2022)
 - 2.5.2 Global Multivalent Influenza Vaccines Revenue and Market Share by Application (2017-2022)
 - 2.5.3 Global Multivalent Influenza Vaccines Sale Price by Application (2017-2022)

3 GLOBAL MULTIVALENT INFLUENZA VACCINES BY COMPANY

3.1 Global Multivalent Influenza Vaccines Breakdown Data by Company

3.1.1 Global Multivalent Influenza Vaccines Annual Sales by Company (2020-2022)

3.1.2 Global Multivalent Influenza Vaccines Sales Market Share by Company (2020-2022)

3.2 Global Multivalent Influenza Vaccines Annual Revenue by Company (2020-2022)

3.2.1 Global Multivalent Influenza Vaccines Revenue by Company (2020-2022)

3.2.2 Global Multivalent Influenza Vaccines Revenue Market Share by Company (2020-2022)

3.3 Global Multivalent Influenza Vaccines Sale Price by Company

3.4 Key Manufacturers Multivalent Influenza Vaccines Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Multivalent Influenza Vaccines Product Location Distribution

3.4.2 Players Multivalent Influenza Vaccines Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR MULTIVALENT INFLUENZA VACCINES BY GEOGRAPHIC REGION

4.1 World Historic Multivalent Influenza Vaccines Market Size by Geographic Region (2017-2022)

4.1.1 Global Multivalent Influenza Vaccines Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Multivalent Influenza Vaccines Annual Revenue by Geographic Region

4.2 World Historic Multivalent Influenza Vaccines Market Size by Country/Region (2017-2022)

4.2.1 Global Multivalent Influenza Vaccines Annual Sales by Country/Region (2017-2022)

4.2.2 Global Multivalent Influenza Vaccines Annual Revenue by Country/Region

4.3 Americas Multivalent Influenza Vaccines Sales Growth

4.4 APAC Multivalent Influenza Vaccines Sales Growth

4.5 Europe Multivalent Influenza Vaccines Sales Growth

4.6 Middle East & Africa Multivalent Influenza Vaccines Sales Growth

5 AMERICAS

5.1 Americas Multivalent Influenza Vaccines Sales by Country

5.1.1 Americas Multivalent Influenza Vaccines Sales by Country (2017-2022)

5.1.2 Americas Multivalent Influenza Vaccines Revenue by Country (2017-2022)

5.2 Americas Multivalent Influenza Vaccines Sales by Type

5.3 Americas Multivalent Influenza Vaccines Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Multivalent Influenza Vaccines Sales by Region

6.1.1 APAC Multivalent Influenza Vaccines Sales by Region (2017-2022)

6.1.2 APAC Multivalent Influenza Vaccines Revenue by Region (2017-2022)

6.2 APAC Multivalent Influenza Vaccines Sales by Type

6.3 APAC Multivalent Influenza Vaccines Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Multivalent Influenza Vaccines by Country

7.1.1 Europe Multivalent Influenza Vaccines Sales by Country (2017-2022)

7.1.2 Europe Multivalent Influenza Vaccines Revenue by Country (2017-2022)

7.2 Europe Multivalent Influenza Vaccines Sales by Type

7.3 Europe Multivalent Influenza Vaccines Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Multivalent Influenza Vaccines by Country

8.1.1 Middle East & Africa Multivalent Influenza Vaccines Sales by Country (2017-2022)

8.1.2 Middle East & Africa Multivalent Influenza Vaccines Revenue by Country (2017-2022)

8.2 Middle East & Africa Multivalent Influenza Vaccines Sales by Type

8.3 Middle East & Africa Multivalent Influenza Vaccines Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Multivalent Influenza Vaccines

10.3 Manufacturing Process Analysis of Multivalent Influenza Vaccines

10.4 Industry Chain Structure of Multivalent Influenza Vaccines

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Multivalent Influenza Vaccines Distributors

11.3 Multivalent Influenza Vaccines Customer

12 WORLD FORECAST REVIEW FOR MULTIVALENT INFLUENZA VACCINES BY GEOGRAPHIC REGION

- 12.1 Global Multivalent Influenza Vaccines Market Size Forecast by Region
 - 12.1.1 Global Multivalent Influenza Vaccines Forecast by Region (2023-2028)
 - 12.1.2 Global Multivalent Influenza Vaccines Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Multivalent Influenza Vaccines Forecast by Type
- 12.7 Global Multivalent Influenza Vaccines Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Sanofi

- 13.1.1 Sanofi Company Information
- 13.1.2 Sanofi Multivalent Influenza Vaccines Product Offered
- 13.1.3 Sanofi Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.1.4 Sanofi Main Business Overview
- 13.1.5 Sanofi Latest Developments

13.2 CSL

- 13.2.1 CSL Company Information
- 13.2.2 CSL Multivalent Influenza Vaccines Product Offered
- 13.2.3 CSL Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.2.4 CSL Main Business Overview
- 13.2.5 CSL Latest Developments

13.3 GSK

- 13.3.1 GSK Company Information
- 13.3.2 GSK Multivalent Influenza Vaccines Product Offered
- 13.3.3 GSK Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.3.4 GSK Main Business Overview
- 13.3.5 GSK Latest Developments

13.4 Viatris

- 13.4.1 Viatris Company Information
- 13.4.2 Viatris Multivalent Influenza Vaccines Product Offered
- 13.4.3 Viatris Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin

(2020-2022)

13.4.4 Viatris Main Business Overview

13.4.5 Viatris Latest Developments

13.5 AstraZeneca

13.5.1 AstraZeneca Company Information

13.5.2 AstraZeneca Multivalent Influenza Vaccines Product Offered

13.5.3 AstraZeneca Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 AstraZeneca Main Business Overview

13.5.5 AstraZeneca Latest Developments

13.6 Hualan Bio

13.6.1 Hualan Bio Company Information

13.6.2 Hualan Bio Multivalent Influenza Vaccines Product Offered

13.6.3 Hualan Bio Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Hualan Bio Main Business Overview

13.6.5 Hualan Bio Latest Developments

13.7 Changchun Institute of Biological

13.7.1 Changchun Institute of Biological Company Information

13.7.2 Changchun Institute of Biological Multivalent Influenza Vaccines Product Offered

13.7.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Changchun Institute of Biological Main Business Overview

13.7.5 Changchun Institute of Biological Latest Developments

13.8 Sinovac

13.8.1 Sinovac Company Information

13.8.2 Sinovac Multivalent Influenza Vaccines Product Offered

13.8.3 Sinovac Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Sinovac Main Business Overview

13.8.5 Sinovac Latest Developments

13.9 Bcht Biotechnology

13.9.1 Bcht Biotechnology Company Information

13.9.2 Bcht Biotechnology Multivalent Influenza Vaccines Product Offered

13.9.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Bcht Biotechnology Main Business Overview

13.9.5 Bcht Biotechnology Latest Developments

13.10 Jiangsu GDK

13.10.1 Jiangsu GDK Company Information

13.10.2 Jiangsu GDK Multivalent Influenza Vaccines Product Offered

13.10.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Jiangsu GDK Main Business Overview

13.10.5 Jiangsu GDK Latest Developments

13.11 KM Biologics

13.11.1 KM Biologics Company Information

13.11.2 KM Biologics Multivalent Influenza Vaccines Product Offered

13.11.3 KM Biologics Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 KM Biologics Main Business Overview

13.11.5 KM Biologics Latest Developments

13.12 ADIMMUNE Corporation

13.12.1 ADIMMUNE Corporation Company Information

13.12.2 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Offered

13.12.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 ADIMMUNE Corporation Main Business Overview

13.12.5 ADIMMUNE Corporation Latest Developments

13.13 Aleph Biomedical

13.13.1 Aleph Biomedical Company Information

13.13.2 Aleph Biomedical Multivalent Influenza Vaccines Product Offered

13.13.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Aleph Biomedical Main Business Overview

13.13.5 Aleph Biomedical Latest Developments

13.14 Shanghai Institute of Biological Products

13.14.1 Shanghai Institute of Biological Products Company Information

13.14.2 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Offered

13.14.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Shanghai Institute of Biological Products Main Business Overview

13.14.5 Shanghai Institute of Biological Products Latest Developments

13.15 Zhongyianke Biotech

13.15.1 Zhongyianke Biotech Company Information

13.15.2 Zhongyianke Biotech Multivalent Influenza Vaccines Product Offered

13.15.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 Zhongyianke Biotech Main Business Overview

13.15.5 Zhongyianke Biotech Latest Developments

13.16 Wuhan Institute of Biological Products

13.16.1 Wuhan Institute of Biological Products Company Information

13.16.2 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Offered

13.16.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2022)

13.16.4 Wuhan Institute of Biological Products Main Business Overview

13.16.5 Wuhan Institute of Biological Products Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Multivalent Influenza Vaccines Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)

Table 2. Multivalent Influenza Vaccines Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)

Table 3. Major Players of Trivalent Inactivated Influenza Vaccine (IIV3)

Table 4. Major Players of Trivalent Live Attenuated Vaccine (LAIV3)

Table 5. Major Players of Quadrivalent Inactivated Influenza Vaccine (IIV4)

Table 6. Global Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)

Table 7. Global Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)

Table 8. Global Multivalent Influenza Vaccines Revenue by Type (2017-2022) & (\$ million)

Table 9. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2017-2022)

Table 10. Global Multivalent Influenza Vaccines Sale Price by Type (2017-2022) & (US\$/Unit)

Table 11. Global Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)

Table 12. Global Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)

Table 13. Global Multivalent Influenza Vaccines Revenue by Application (2017-2022)

Table 14. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2017-2022)

Table 15. Global Multivalent Influenza Vaccines Sale Price by Application (2017-2022) & (US\$/Unit)

Table 16. Global Multivalent Influenza Vaccines Sales by Company (2020-2022) & (K Units)

Table 17. Global Multivalent Influenza Vaccines Sales Market Share by Company (2020-2022)

Table 18. Global Multivalent Influenza Vaccines Revenue by Company (2020-2022) (\$ Millions)

Table 19. Global Multivalent Influenza Vaccines Revenue Market Share by Company (2020-2022)

Table 20. Global Multivalent Influenza Vaccines Sale Price by Company (2020-2022) & (US\$/Unit)

- Table 21. Key Manufacturers Multivalent Influenza Vaccines Producing Area Distribution and Sales Area
- Table 22. Players Multivalent Influenza Vaccines Products Offered
- Table 23. Multivalent Influenza Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- Table 24. New Products and Potential Entrants
- Table 25. Mergers & Acquisitions, Expansion
- Table 26. Global Multivalent Influenza Vaccines Sales by Geographic Region (2017-2022) & (K Units)
- Table 27. Global Multivalent Influenza Vaccines Sales Market Share Geographic Region (2017-2022)
- Table 28. Global Multivalent Influenza Vaccines Revenue by Geographic Region (2017-2022) & (\$ millions)
- Table 29. Global Multivalent Influenza Vaccines Revenue Market Share by Geographic Region (2017-2022)
- Table 30. Global Multivalent Influenza Vaccines Sales by Country/Region (2017-2022) & (K Units)
- Table 31. Global Multivalent Influenza Vaccines Sales Market Share by Country/Region (2017-2022)
- Table 32. Global Multivalent Influenza Vaccines Revenue by Country/Region (2017-2022) & (\$ millions)
- Table 33. Global Multivalent Influenza Vaccines Revenue Market Share by Country/Region (2017-2022)
- Table 34. Americas Multivalent Influenza Vaccines Sales by Country (2017-2022) & (K Units)
- Table 35. Americas Multivalent Influenza Vaccines Sales Market Share by Country (2017-2022)
- Table 36. Americas Multivalent Influenza Vaccines Revenue by Country (2017-2022) & (\$ Millions)
- Table 37. Americas Multivalent Influenza Vaccines Revenue Market Share by Country (2017-2022)
- Table 38. Americas Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)
- Table 39. Americas Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)
- Table 40. Americas Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)
- Table 41. Americas Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)

Table 42. APAC Multivalent Influenza Vaccines Sales by Region (2017-2022) & (K Units)

Table 43. APAC Multivalent Influenza Vaccines Sales Market Share by Region (2017-2022)

Table 44. APAC Multivalent Influenza Vaccines Revenue by Region (2017-2022) & (\$ Millions)

Table 45. APAC Multivalent Influenza Vaccines Revenue Market Share by Region (2017-2022)

Table 46. APAC Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)

Table 47. APAC Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)

Table 48. APAC Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)

Table 49. APAC Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)

Table 50. Europe Multivalent Influenza Vaccines Sales by Country (2017-2022) & (K Units)

Table 51. Europe Multivalent Influenza Vaccines Sales Market Share by Country (2017-2022)

Table 52. Europe Multivalent Influenza Vaccines Revenue by Country (2017-2022) & (\$ Millions)

Table 53. Europe Multivalent Influenza Vaccines Revenue Market Share by Country (2017-2022)

Table 54. Europe Multivalent Influenza Vaccines Sales by Type (2017-2022) & (K Units)

Table 55. Europe Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)

Table 56. Europe Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)

Table 57. Europe Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)

Table 58. Middle East & Africa Multivalent Influenza Vaccines Sales by Country (2017-2022) & (K Units)

Table 59. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Country (2017-2022)

Table 60. Middle East & Africa Multivalent Influenza Vaccines Revenue by Country (2017-2022) & (\$ Millions)

Table 61. Middle East & Africa Multivalent Influenza Vaccines Revenue Market Share by Country (2017-2022)

Table 62. Middle East & Africa Multivalent Influenza Vaccines Sales by Type

(2017-2022) & (K Units)

Table 63. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Type (2017-2022)

Table 64. Middle East & Africa Multivalent Influenza Vaccines Sales by Application (2017-2022) & (K Units)

Table 65. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)

Table 66. Key Market Drivers & Growth Opportunities of Multivalent Influenza Vaccines

Table 67. Key Market Challenges & Risks of Multivalent Influenza Vaccines

Table 68. Key Industry Trends of Multivalent Influenza Vaccines

Table 69. Multivalent Influenza Vaccines Raw Material

Table 70. Key Suppliers of Raw Materials

Table 71. Multivalent Influenza Vaccines Distributors List

Table 72. Multivalent Influenza Vaccines Customer List

Table 73. Global Multivalent Influenza Vaccines Sales Forecast by Region (2023-2028) & (K Units)

Table 74. Global Multivalent Influenza Vaccines Sales Market Forecast by Region

Table 75. Global Multivalent Influenza Vaccines Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 76. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Region (2023-2028)

Table 77. Americas Multivalent Influenza Vaccines Sales Forecast by Country (2023-2028) & (K Units)

Table 78. Americas Multivalent Influenza Vaccines Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 79. APAC Multivalent Influenza Vaccines Sales Forecast by Region (2023-2028) & (K Units)

Table 80. APAC Multivalent Influenza Vaccines Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 81. Europe Multivalent Influenza Vaccines Sales Forecast by Country (2023-2028) & (K Units)

Table 82. Europe Multivalent Influenza Vaccines Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 83. Middle East & Africa Multivalent Influenza Vaccines Sales Forecast by Country (2023-2028) & (K Units)

Table 84. Middle East & Africa Multivalent Influenza Vaccines Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 85. Global Multivalent Influenza Vaccines Sales Forecast by Type (2023-2028) & (K Units)

Table 86. Global Multivalent Influenza Vaccines Sales Market Share Forecast by Type (2023-2028)

Table 87. Global Multivalent Influenza Vaccines Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 88. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Type (2023-2028)

Table 89. Global Multivalent Influenza Vaccines Sales Forecast by Application (2023-2028) & (K Units)

Table 90. Global Multivalent Influenza Vaccines Sales Market Share Forecast by Application (2023-2028)

Table 91. Global Multivalent Influenza Vaccines Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 92. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Application (2023-2028)

Table 93. Sanofi Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 94. Sanofi Multivalent Influenza Vaccines Product Offered

Table 95. Sanofi Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 96. Sanofi Main Business

Table 97. Sanofi Latest Developments

Table 98. CSL Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 99. CSL Multivalent Influenza Vaccines Product Offered

Table 100. CSL Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 101. CSL Main Business

Table 102. CSL Latest Developments

Table 103. GSK Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 104. GSK Multivalent Influenza Vaccines Product Offered

Table 105. GSK Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 106. GSK Main Business

Table 107. GSK Latest Developments

Table 108. Viatris Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 109. Viatris Multivalent Influenza Vaccines Product Offered

Table 110. Viatris Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2020-2022)

Table 111. Viatris Main Business

Table 112. Viatris Latest Developments

Table 113. AstraZeneca Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 114. AstraZeneca Multivalent Influenza Vaccines Product Offered

Table 115. AstraZeneca Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 116. AstraZeneca Main Business

Table 117. AstraZeneca Latest Developments

Table 118. Hualan Bio Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 119. Hualan Bio Multivalent Influenza Vaccines Product Offered

Table 120. Hualan Bio Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 121. Hualan Bio Main Business

Table 122. Hualan Bio Latest Developments

Table 123. Changchun Institute of Biological Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 124. Changchun Institute of Biological Multivalent Influenza Vaccines Product Offered

Table 125. Changchun Institute of Biological Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 126. Changchun Institute of Biological Main Business

Table 127. Changchun Institute of Biological Latest Developments

Table 128. Sinovac Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 129. Sinovac Multivalent Influenza Vaccines Product Offered

Table 130. Sinovac Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 131. Sinovac Main Business

Table 132. Sinovac Latest Developments

Table 133. Bcht Biotechnology Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 134. Bcht Biotechnology Multivalent Influenza Vaccines Product Offered

Table 135. Bcht Biotechnology Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 136. Bcht Biotechnology Main Business

Table 137. Bcht Biotechnology Latest Developments

- Table 138. Jiangsu GDK Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
- Table 139. Jiangsu GDK Multivalent Influenza Vaccines Product Offered
- Table 140. Jiangsu GDK Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 141. Jiangsu GDK Main Business
- Table 142. Jiangsu GDK Latest Developments
- Table 143. KM Biologics Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
- Table 144. KM Biologics Multivalent Influenza Vaccines Product Offered
- Table 145. KM Biologics Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 146. KM Biologics Main Business
- Table 147. KM Biologics Latest Developments
- Table 148. ADIMMUNE Corporation Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
- Table 149. ADIMMUNE Corporation Multivalent Influenza Vaccines Product Offered
- Table 150. ADIMMUNE Corporation Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 151. ADIMMUNE Corporation Main Business
- Table 152. ADIMMUNE Corporation Latest Developments
- Table 153. Aleph Biomedical Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
- Table 154. Aleph Biomedical Multivalent Influenza Vaccines Product Offered
- Table 155. Aleph Biomedical Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 156. Aleph Biomedical Main Business
- Table 157. Aleph Biomedical Latest Developments
- Table 158. Shanghai Institute of Biological Products Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
- Table 159. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Offered
- Table 160. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 161. Shanghai Institute of Biological Products Main Business
- Table 162. Shanghai Institute of Biological Products Latest Developments
- Table 163. Zhongyianke Biotech Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors
- Table 164. Zhongyianke Biotech Multivalent Influenza Vaccines Product Offered

Table 165. Zhongyianke Biotech Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 166. Zhongyianke Biotech Main Business

Table 167. Zhongyianke Biotech Latest Developments

Table 168. Wuhan Institute of Biological Products Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors

Table 169. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Offered

Table 170. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 171. Wuhan Institute of Biological Products Main Business

Table 172. Wuhan Institute of Biological Products Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Multivalent Influenza Vaccines
- Figure 2. Multivalent Influenza Vaccines Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Multivalent Influenza Vaccines Sales Growth Rate 2017-2028 (K Units)
- Figure 7. Global Multivalent Influenza Vaccines Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. Multivalent Influenza Vaccines Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Trivalent Inactivated Influenza Vaccine (IIV3)
- Figure 10. Product Picture of Trivalent Live Attenuated Vaccine (LAIV3)
- Figure 11. Product Picture of Quadrivalent Inactivated Influenza Vaccine (IIV4)
- Figure 12. Global Multivalent Influenza Vaccines Sales Market Share by Type in 2021
- Figure 13. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2017-2022)
- Figure 14. Multivalent Influenza Vaccines Consumed in 6 Months to 3 Years
- Figure 15. Global Multivalent Influenza Vaccines Market: 6 Months to 3 Years (2017-2022) & (K Units)
- Figure 16. Multivalent Influenza Vaccines Consumed in Above 3 Years
- Figure 17. Global Multivalent Influenza Vaccines Market: Above 3 Years (2017-2022) & (K Units)
- Figure 18. Global Multivalent Influenza Vaccines Sales Market Share by Application (2017-2022)
- Figure 19. Global Multivalent Influenza Vaccines Revenue Market Share by Application in 2021
- Figure 20. Multivalent Influenza Vaccines Revenue Market by Company in 2021 (\$ Million)
- Figure 21. Global Multivalent Influenza Vaccines Revenue Market Share by Company in 2021
- Figure 22. Global Multivalent Influenza Vaccines Sales Market Share by Geographic Region (2017-2022)
- Figure 23. Global Multivalent Influenza Vaccines Revenue Market Share by Geographic Region in 2021
- Figure 24. Global Multivalent Influenza Vaccines Sales Market Share by Region (2017-2022)

- Figure 25. Global Multivalent Influenza Vaccines Revenue Market Share by Country/Region in 2021
- Figure 26. Americas Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
- Figure 27. Americas Multivalent Influenza Vaccines Revenue 2017-2022 (\$ Millions)
- Figure 28. APAC Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
- Figure 29. APAC Multivalent Influenza Vaccines Revenue 2017-2022 (\$ Millions)
- Figure 30. Europe Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
- Figure 31. Europe Multivalent Influenza Vaccines Revenue 2017-2022 (\$ Millions)
- Figure 32. Middle East & Africa Multivalent Influenza Vaccines Sales 2017-2022 (K Units)
- Figure 33. Middle East & Africa Multivalent Influenza Vaccines Revenue 2017-2022 (\$ Millions)
- Figure 34. Americas Multivalent Influenza Vaccines Sales Market Share by Country in 2021
- Figure 35. Americas Multivalent Influenza Vaccines Revenue Market Share by Country in 2021
- Figure 36. United States Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)
- Figure 37. Canada Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)
- Figure 38. Mexico Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)
- Figure 39. Brazil Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)
- Figure 40. APAC Multivalent Influenza Vaccines Sales Market Share by Region in 2021
- Figure 41. APAC Multivalent Influenza Vaccines Revenue Market Share by Regions in 2021
- Figure 42. China Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)
- Figure 43. Japan Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)
- Figure 44. South Korea Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)
- Figure 45. Southeast Asia Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)
- Figure 46. India Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)
- Figure 47. Australia Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)
- Figure 48. Europe Multivalent Influenza Vaccines Sales Market Share by Country in 2021

Figure 49. Europe Multivalent Influenza Vaccines Revenue Market Share by Country in 2021

Figure 50. Germany Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)

Figure 51. France Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)

Figure 52. UK Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)

Figure 53. Italy Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)

Figure 54. Russia Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)

Figure 55. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Country in 2021

Figure 56. Middle East & Africa Multivalent Influenza Vaccines Revenue Market Share by Country in 2021

Figure 57. Egypt Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)

Figure 58. South Africa Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)

Figure 59. Israel Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)

Figure 60. Turkey Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)

Figure 61. GCC Country Multivalent Influenza Vaccines Revenue Growth 2017-2022 (\$ Millions)

Figure 62. Manufacturing Cost Structure Analysis of Multivalent Influenza Vaccines in 2021

Figure 63. Manufacturing Process Analysis of Multivalent Influenza Vaccines

Figure 64. Industry Chain Structure of Multivalent Influenza Vaccines

Figure 65. Channels of Distribution

Figure 66. Distributors Profiles

I would like to order

Product name: Global Multivalent Influenza Vaccines Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/G93E974CA330EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G93E974CA330EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970